News

Despite ongoing U.S. federal initiatives to promote onshoring and the imposition of pharmaceutical import tariffs, biopharmaceutical companies continue to expand their manufacturing partnerships in Europe. According to industry analysis from GlobalData, this trend reflects a strategic effort by drugmakers to mitigate risks associated with supply chain vulnerabilities and geopolitical trade tensions. Europe has emerged as an attractive and well-established hub for pharmaceutical manufacturing, particularly for products destined for the U.S. market. In 2025 alone, Europe secured more than three times as many contract manufacturing (CM) deals as the United States, with a total of 34 agreements recorded. Germany, recognized as Europe's leading drug producer, dominated this landscape by capturing 12 of these deals, maintaining an average of 9 CM deals per year over the past five years for U.S.-market drugs.

The persistence of this outward migration of manufacturing capacity occurs even in the face of a 15% tariff on EU pharmaceuticals, negotiated in August under previous trade policies. Of the 14 U.S.-based pharmaceutical companies that outsourced manufacturing in the past year, nine—including major players like Johnson & Johnson and Vertex Pharmaceuticals—committed to 13 deals specifically in Europe. This diversification strategy is driven by the need to hedge against persistent uncertainties, including potential escalations in international trade policies under evolving administrations. The data highlights how biopharma executives are prioritizing resilience over short-term cost pressures, leveraging Europe's advanced infrastructure, skilled workforce, and regulatory environment to ensure steady drug supply.

Recent high-profile investments underscore this shift. Eli Lilly, determined to avoid future manufacturing bottlenecks, pledged $3 billion in November to construct a state-of-the-art tablet manufacturing plant in Katwijk, Netherlands. This facility will enhance production capabilities for critical oral solid dosage forms, supporting Lilly's expanding portfolio amid surging demand for therapies like GLP-1 agonists. Similarly, Novo Nordisk committed $506 million last month to upgrade and expand its manufacturing site in Athlone, Ireland, focusing on tablet production to meet global needs. These investments not only bolster local economies but also position European CMOs as indispensable partners in the global pharma supply chain.

For pharmaceutical executives and CRO/CMO leaders, this trend signals several strategic implications. First, it emphasizes the importance of multi-regional manufacturing footprints to navigate tariff risks and raw material disruptions. Germany's dominance, with its cluster of specialized facilities in cleanroom operations, process machinery, and quality assurance, makes it a prime destination for outsourcing complex formulations and active pharmaceutical ingredients (APIs). Companies like Vertex, known for its work in cystic fibrosis treatments, are leveraging European partners for scalability without compromising on compliance standards set by the FDA and EMA.

Procurement professionals should note the competitive dynamics this creates. With U.S. CM deal volumes declining sharply post-COVID—due to fluctuating vaccine demand—European providers have ramped up capacity. Between 2023 and 2024, deal activity rebounded across regions, but Europe's growth outpaced others. This could lead to improved negotiating power for buyers seeking pharmaceutical manufacturing equipment, validation services, and supply chain solutions. However, regulatory teams must remain vigilant about harmonizing standards, as cross-Atlantic deals require meticulous documentation for pharmaceutical quality assurance and legislation compliance.

R&D heads and technology vendors will find opportunities in Europe's push for innovation. Facilities like those in Katwijk and Athlone are integrating advanced pharmaceutical process machinery, laboratory automation, and robotics to optimize yields and reduce timelines. This aligns with broader industry moves toward digital transformation, where AI-driven predictive maintenance and real-time monitoring enhance pharmaceutical materials handling and cold chain logistics. For instance, upgraded sites are incorporating spectroscopy for in-process controls and cleanroom solutions to meet stringent validation requirements.

Looking ahead, economic and regional development in pharma hubs like the Netherlands and Ireland will likely accelerate. These investments create jobs in high-skill areas such as pharmaceutical excipients formulation, tableting, and encapsulation, while fostering partnerships in contract services. Management consulting firms advise executives to assess tariff scenarios through scenario planning, ensuring contracts include flexibility clauses for pharmaceutical outsourcing. Safety and security measures, including cybersecurity for supply chain data, are also critical as digital integration grows.

In summary, the surge in European CM deals represents a calculated pivot by U.S. biopharma toward diversified, resilient operations. This B2B shift benefits manufacturing managers by providing access to cutting-edge infrastructure, while challenging U.S. policymakers to refine onshoring incentives. Pharmaceutical-Tech.com will continue monitoring these developments for implications on global operations.